Navigation Links
enter in Medical Technology

Critical Pharmaceuticals Enter Sustained Release hGH Arena

Preclinical Results of New Somatropin Formulation Demonstrate Advantages Over Existing Once-Daily Product NOTTINGHAM, England, October 1 /PRNewswire/ -- Critical Pharmaceuticals, the Nottingham, UK-based speciality pharmaceuticals company, today announced that the successful...

Omeros and The Parkinson's Institute and Clinical Center Enter into a Collaboration Agreement to Evaluate Novel Target for the Treatment of Movement Disorders

SEATTLE and SUNNYVALE, Calif., Sept. 17 /PRNewswire/ -- Omeros Corporation and The Parkinson's Institute and Clinical Center today announced that they have entered into a collaboration to evaluate a novel target, proprietary to Omeros, for the treatment of movement disorders. The collaboration...

Siemens and LabCorp Enter Agreement to Co-Develop New Clinical Diagnostic Tests

DEERFIELD, Ill., May 8 /PRNewswire-FirstCall/ -- Siemens Healthcare and Laboratory Corporation of America(R) Holdings (LabCorp(R)) today announced that they have entered a non-exclusive agreement to discuss future possibilities to co-develop new clinical diagnostic tests in the areas of compan...

Successful Clinical Trials and Launch in New Zealand Spurs Phloe to Enter US Market

WELLINGTON, New Zealand, Feb. 4 /PRNewswire/ -- Innovative New Zealand nutraceutical manufacturer, Vital Foods, has appointed David Mastroianni, founder and principal of leading US consulting company, Natural Growth LLC, as the Chief Executive for their US based business. Mr Mastroianni will b...

Derma Sciences to Enter Phase II Development of Wound Healing Product That May Use Body's Own Naturally Occurring Stem Cells

Appoints U.S. Biotest to Oversee Trials PRINCETON, N.J., Jan. 24 /PRNewswire-FirstCall/ -- Derma Sciences, Inc. (OTC Bulletin Board: DSCI), a provider of advanced wound care products, announced today that it has signed a clinical services agreement with San Luis Obispo-based, p...

Ardea Biosciences' Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients

- Multi-Center Phase 1 Trial to Commence - CARLSBAD, Calif., Oct. 1 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. (Pink Sheets: ARDC), a company focused on the discovery and development of small-molecule therapeutics for the treatment of viral diseases, cancer and inflammato...

Intellect Neurosciences, Inc. and CHDI, Inc. Enter Into Compound Testing Agreement to Evaluate OXIGON(TM) as a Potential Treatment for Huntington Disease

Agreement demonstrates broad potential use of Intellect's clinical candidate NEW YORK, Sept. 20 /PRNewswire-FirstCall/ -- Intellect Neurosciences, Inc. (OTC Bulletin Board: ILNS), a biopharmaceutical company focused on the development of disease-modifying thera...

Genetic Analysis Systems Enter the Clinical Mainstream

Like many other diagnostic regimes that were previously restricted to large specialty laboratories, genetic analysis is entering the clinical mainstream. Smaller, simpler analyzer systems are now suitable and affordable for hospital or large physicians group labs, while some genetic test kits are ...

Radius' Investigational Bone Anabolic Agent, BA058, Increased Bone Mineral Density (BMD) at Key Fracture Sites in Phase 2 Clinical Trial in Postmenopausal Osteoporosis

...bone-mineral density. A 50-year-old woman in the U.S. has a 40 percent lifetime risk of osteoporotic fracture. Twenty percent of hip-fracture patients enter long-term care, and half of this group never returns to living independently. About Radius (www.radiuspharm.com) Radius is a leading compan...

NOVAVAX Achieves Pandemic H1N1 Influenza Production Milestone

... which may result in delays and increased costs; the success of the Company's foreign joint venture and licensing agreements; the Company's ability to enter into future collaborations with industry partners and governments and the terms, timing and success of any such collaboration; the cost of filing, pro...

Nektar Therapeutics Reports Second Quarter 2009 Financial Results

... of the company's pipeline of proprietary drug candidates, the value and potential of the company's technology platform, and the company's position to enter into new strategic collaborations with third parties. These forward-looking statements involve numerous risks and uncertainties, including but not li...

Is Your Hair Taking a Break?

...al growth cycle. However, telogen effluvium occurs as a result of the body's natural physiologic response to some form of stress, causing more hair to enter the rest phase than the normal 10 percent. For example, surgery, childbirth, dramatic weight loss (including gastric bypass surgery), the death of a l...

Idenix Pharmaceuticals Successfully Completes Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)

...call please dial 800-774-5358 U.S./Canada or 706-758-9475 International and enter passcode 20088902 or to listen to a live webcast and view accompanying slid...lay, please dial 800-642-1687 U.S./Canada or 706-645-9291 International and enter passcode 20088902. An archived webcast will also be available for two weeks...

Velos, Inc. Releases Software to Support Cancer Centers With New Workflow and Content for NCI Clinical Trials Reporting Program

...gram is to establish a comprehensive database containing regularly updated information on all NCI-funded interventional clinical trials. Grantees will enter specific information about each clinical trial into the database. NCI will use this information to coordinate research efforts to optimize our nation'...

Orkin Warns of Four Pests to Avoid this Fourth of July

...inging insects: Seal food tightly in containers. Cover soda cans or drink from clear cups. Yellow jackets love sugar and may enter cans unseen. Empty and wash garbage cans regularly. Mow yards to make ant mounds visible and avoidable. About Orkin...

Cordex Signs European Development Partnership for ATPotent(TM) Sperm Motility Drug

...m infertile males with asthenozoospermia were used. "We are pleased to enter this agreement with CTI as we feel it will accelerate the development of AT...which are in late stages of clinical development. ATPace(TM) is expected to enter a Phase 2b/3 clinical trial for the treatment of paroxysmal supraventricula...

DOR BioPharma Receives EMEA Agreement on the Design of its Confirmatory Phase 3 Clinical Trial of orBec(R) in GI GVHD

...ent efforts, that it will be able to successfully obtain any further grants and awards, maintain its existing grants which are subject to performance, enter into any biodefense procurement contracts with the US Government or other countries, that the US Congress may not pass any legislation that would prov...

New One-Year Data from REMICADE(R) SONIC Trial Show Sustained Efficacy Compared with Azathioprine in Treatment of Crohn's Disease

... weeks. The proportion of patients achieving steroid-free remission among the overall randomized population (N=508), including individuals who did not enter the study extension and were assumed to be non-responders to therapy or not in steroid-free remission at week 50, was 46 percent of patients receiving...

Researchers at the Karmanos Cancer Institute in Detroit Discover Feasibility of Chemotherapy Alternative

...urer Roche to perform the study. Dr. Yoo said Karmanos continues to enroll patients in the Phase II study and hopes that down the road, the study will enter a third phase. "We thought it was a good study, one that explores the effects of low-dose, long-term oral chemotherapy treatments," said Dr. Yoo....

Perceptive Informatics Enhances Investigator Application of New RECIST Version in Imaging-Based Oncology Trials

...h and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business, including, but not limited to, the successful business integration and anticipated synergy achievements in connection with...

PAREXEL Reaches Milestone in Management of Oncology Trials Over Last Five Years Involving 175,000 Patients Worldwide

...h and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business, including, but not limited to, the successful business integration and anticipated synergy achievements in connection with...

GreenBytes Wards Off Germs and Costly Computer Repairs

...me of the germiest surfaces around should be enough to make you get these systems professionally cleaned," Glass says. "But dust, dirt, and grime that enter your computer workstations and office equipment can cause your systems to use up to 73 percent more electricity. In fact, the four most common and cos...

Human Genome Sciences Submits Biologics License Application to FDA for ABthrax(TM)

...ive antigen binds to the anthrax toxin receptor on cell surfaces and forms a protein-receptor complex that makes it possible for the anthrax toxins to enter the cells. Raxibacumab blocks the binding of protective antigen to cell surfaces and prevents the anthrax toxins from entering and killing the cells. ...

Addrenex Pharmaceuticals Expands Product Pipeline by Licensing New Drug to Treat Narcolepsy

...rovides Addrenex with its fourth drug candidate to enter clinical trials in three years. Each of Addrenex's...safe and well tolerated. "We are delighted to enter into a partnership with an experienced company suc... & Development, and ADX-N05, which is ready to enter phase 2 trials. In addition to drug development, S...

One Step Closer: Novel Opioid Receptor Compound in Phase I Clinical Trials

...al Institutes of Health. "I didn't do it myself," Wentland said. "With the OTC, it went very smoothly. In the last 39 years I have had many drugs enter the clinic and then fail. And now I'm here again with another chance and I'm absolutely proud of our entire team. The only way academic research colla...

Alexza Reports 2009 First Quarter Financial Results and Updates Clinical Pipeline Status

...e live conference call via phone, dial 888-679-8038. International callers may access the live call by dialing 617-213-4850. The reference number to enter the call is 78345594. The replay of the conference call may be accessed via the Internet, at www.alexza.com , or via phone at 888-286-8010 for...

Perceptive Informatics Survey Results Reveal Top Barriers to Implementing Adaptive Trial Designs

...h and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business, including, but not limited to, the successful business integration and anticipated synergy achievements in connection with...

Ipsogen Expands its US Market Presence Through Licensing Agreement With ARUP Laboratories for the Commercialization of JAK2 Molecular Diagnostic Assays

...ntellectual Property position of Ipsogen's JAK2 patent portfolio," said Vincent Fert, Chairman and CEO of Ipsogen. "We are pleased to have ARUP enter into our licensing program. This agreement supports our strategy to fully supply the US JAK2 market through a combination of strategic licensing arran...

Perceptive Informatics Introduces Medical Imaging Methodology to Accelerate Development Decisions About Alzheimer's Treatments

...h and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business, including, but not limited to, the successful business integration and anticipated synergy achievements in connection with...

Investigational Genetic Test May Help Address Common Problems in Prostate Cancer Diagnosis

...iv) the risk that we may not be able to compete effectively, (v) the risk that we may not be able to maintain our current corporate collaborations and enter into new corporate collaborations or customer contracts, and (vi) our dependence on third parties for the distribution of some of our products. The fo...

Gen-Probe and DiagnoCure Amend Collaboration Agreement Surrounding PCA3-Based Prostate Cancer Tests

...y not develop as expected, (iv) we may not be able to compete effectively, (v) we may not be able to maintain our current corporate collaborations and enter into new corporate collaborations or customer contracts, and (vi) we are dependent on third parties for the distribution of some of our products. The...

InterMune Reports Presentation of Triple Combination Study of ITMN-191 at European Association for the Study of the Liver (EASL)

...one analog named ITMN-520. The hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 (referred to as R7227 at Roche) expected to enter Phase 2b in the summer of 2009 and a second-generation HCV protease inhibitor research program. For additional information about InterMune and its R&...

ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients

...ks related to competition from other biotechnology and pharmaceutical companies, its effectiveness at managing its financial resources, its ability to enter into transactions around its product candidates, its ability to successfully develop and market products, difficulties or delays in its preclinical st...

University of California Los Angeles Selects Velos eResearch

...RI network sites. Previously, data was transmitted by email and fax and manually keyed into the old database. With the new system, the TORI sites will enter their own data directly into Velos. "They can go online, view the studies available at their site and track their patients through Velos," Ryba s...

Simbionix and Johnson & Johnson LLC Announce Distribution Agreement at Russia and the CIS Countries

...sive rights to distribute Simbionix's line of advanced medical simulators in hospitals in the Russia and CIS countries. "We are very excited to enter into this collaboration with Johnson & Johnson LLC to bring our advanced simulators into the Russian republic' hospitals, teaching facilities and ...

Prometheus and Rosetta Genomics Announce License and Collaboration Agreement

...ee products, and has established itself as a leader in the development of novel, molecular diagnostic products based on microRNAs. We are delighted to enter into this comprehensive partnership with Prometheus," said Amir Avniel, President and Chief Executive Officer of Rosetta Genomics. "With Prometheus th...

Glycotex' Investigational Compound GLYC-101 Achieves Accelerated Wound Closure Based on Interim Analysis

...ailure of our products to obtain such approval; uncertainties or differences in interpretation of clinical trial results; our inability to maintain or enter into, and the risks resulting from, our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commerc...

Pharmos Issues Business Update on Dextofisopam Trial and Financing

...rial is now essentially fully enrolled. Patient screening was stopped on March 13, 2009 and when those patients who qualify from the screening process enter the trial, the trial will be closed. The Company expects the final trial size to be about 320 patients. The treatment period is 12 weeks with a f...

DOR BioPharma, Inc. Executes $400,000 Equity Investment Agreement With Numoda Corporation

...ent efforts, that it will be able to successfully obtain any further grants and awards, maintain its existing grants which are subject to performance, enter into any biodefense procurement contracts with the US Government or other countries, that the US Congress may not pass any legislation that would prov...

DURECT Reports Positive Phase IIb Data from TRANSDU(TM)-Sufentanil Clinical Program

...titration regimens and dose conversion ratios expected to be utilized in the Phase III program) and regulatory pathway for approval, our intentions to enter into collaborations or further develop the program are forward-looking statements involving risks and uncertainties that can cause actual results to d...
Other Tags
(Date:7/25/2014)... WA Nearly 600 scientists from 25 countries ... Genetics Meeting organized by the Genetics Society of ... Washington in Seattle. The conference will feature close ... research results on topics including gene expression and ... emerging technologies, evolution, aging, and a variety of ...
(Date:7/25/2014)... consume the healthcare community and remain priority ... To address the worldwide crisis of obesity ... global leaders in diabetes, epidemiology and public ... and development of diverse intervention programs in ... This book on "Global Health Perspectives in ...
(Date:7/25/2014)... pleiotropic factor characterized by the existence of numerous ... confer to the protein deeply different characteristics. NRG1 ... occurring during development and the different phases occurring ... axon regrowth, remyelination and target reinnervation, Researchers at ... the soluble NRG1 upregulation observed in Schwann cells ...
Breaking Biology News(10 mins):Yeast meeting to showcase latest breakthroughs in genetics and molecular biology 2What constitutes an effective response to the global 'diabesity' tsunami? 2
(Date:7/25/2014)... (PRWEB) July 25, 2014 Drexel University ... D. Weber, MD, MS, FACP, has been appointed vice dean ... will join Drexel from The Commonwealth Medical College, where she ... dean for clinical affairs, and professor of medicine. , ... Commonwealth Medical College, Weber had a major role in many ...
(Date:7/25/2014)... News) -- Babies seem to learn even before they,re ... women are 34 weeks pregnant, their unborn babies can ... a familiar nursery rhyme, the researchers report. "The ... in the developing fetus," Charlene Krueger, nursing researcher and ... Nursing, said in a university news release. "This research ...
(Date:7/25/2014)... sent patients to designated cardiac receiving centers dramatically increased ... in Arizona, according to a study published online yesterday ... , "We knew lives would be saved if the ... arrest care and we were able to get cardiac ... done for Level 1 trauma patients," said lead study ...
(Date:7/25/2014)... Parkulture is proud to ... parkour instructor, Jared “JJ” Woods, will be competing on ... Ninja Warrior. The show will premiere on local affiliates ... rerun on the new Esquire Network on Tuesday, July ... has been balancing careers as a professional stuntman for ...
(Date:7/25/2014)... 2014 In today’s technological era, every ... supporting devices. This benefits the organization in various ways. ... attacks which can destroy the confidential information and processes ... and Compliance (EGRC) manage and protect the enterprise from ... cause loss in dollars to the comp may. The ...
Breaking Medicine News(10 mins):Health News:Valerie D. Weber, MD, Appointed Vice Dean for Education at Drexel University College of Medicine 2Health News:Valerie D. Weber, MD, Appointed Vice Dean for Education at Drexel University College of Medicine 3Health News:Rhymes Reveal Evidence of Learning in the Womb 2Health News:New EMS system in Arizona dramatically improves survival from cardiac arrest 2Health News:New EMS system in Arizona dramatically improves survival from cardiac arrest 3Health News:Jared “JJ” Woods Prepares for American Ninja Warrior City Finals 2Health News:Jared “JJ” Woods Prepares for American Ninja Warrior City Finals 3Health News:North America Enterprise Governance, Risk, and Compliance Market is Expected to Reach $3,972.6 Million in 2018 - New Report by MicroMarket Monitor 2Health News:North America Enterprise Governance, Risk, and Compliance Market is Expected to Reach $3,972.6 Million in 2018 - New Report by MicroMarket Monitor 3Health News:North America Enterprise Governance, Risk, and Compliance Market is Expected to Reach $3,972.6 Million in 2018 - New Report by MicroMarket Monitor 4Health News:North America Enterprise Governance, Risk, and Compliance Market is Expected to Reach $3,972.6 Million in 2018 - New Report by MicroMarket Monitor 5Health News:North America Enterprise Governance, Risk, and Compliance Market is Expected to Reach $3,972.6 Million in 2018 - New Report by MicroMarket Monitor 6
Other Contents